NewAmsterdam Pharma to Go Public via Business Combination with Frazier Lifesciences Acquisition Corporation (FLAC)

NLS Pharmaceutics Merges with Kadimastem to Form NewCelX

June 27, 2025

Biotechnology

NLS Pharmaceutics Ltd. completed a $3.0 million equity financing to support its pending merger with Kadimastem Ltd.; the transaction closed and the combined company was re-named NewCelX Ltd. The deal brings together NLS's CNS-focused pipeline and Kadimastem's cell therapy programs (AstroRx and IsletRx) to advance clinical development for ALS, diabetes and other regenerative-medicine indications.

FitLife Brands Acquires Substantially All Assets of MusclePharm Corporation

October 10, 2023

Consumer Products

FitLife Brands, Inc. (Nasdaq: FTLF) closed on October 10, 2023 the acquisition of substantially all of the assets of MusclePharm Corporation via a Section 363 bankruptcy asset purchase for approximately $18.5 million in cash. The purchase — financed with a $10.0 million term loan from First Citizens Bank and FitLife’s cash — transferred MusclePharm’s brands and assets to FitLife while FitLife assumed none of MusclePharm’s liabilities except de minimis cure costs.

Flourish Research (NMS Capital) Recapitalizes AMC Research and Central Research Associates

May 18, 2023

Healthcare Services

NMS Capital portfolio company Flourish Research partnered with company management to recapitalize AMC Research, LLC (Charlotte, NC) and Central Research Associates (Birmingham, AL). The transactions expand Flourish’s clinical research site network—augmenting its Alzheimer’s capabilities and adding scale in cardiology/metabolic/renal, vaccine and other therapeutic areas; terms were not disclosed.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

Flourish Research / NMS Capital Recapitalize Excel Medical Clinical Trials

October 14, 2021

Healthcare Services

NMS Capital portfolio company Flourish Research partnered with Excel Medical Clinical Trials in a recapitalization. The Boca Raton, Florida-based clinical research site, founded by Dr. Seth Baum and focused on cardiology indications, will join Flourish's site network to expand the platform's geographic footprint and therapeutic capabilities; terms were not disclosed and management will remain in place.

Signet, Bionpharma and GMS Form Pharma Nobis to Acquire Fagron's U.S. Contract Manufacturing Business

February 4, 2022

Pharmaceuticals

An investor consortium led by Signet Healthcare Partners with Bionpharma, Inc. and GMS Capital Partners formed Pharma Nobis, LLC to acquire Fagron's U.S. contract manufacturing business and manufacturing facility in Texarkana, Texas. Fagron will retain a 20% interest in the new company; Todd Daviau was named CEO and the investors said they will seek to grow the contract manufacturing and private-label capabilities for consumer healthcare and retail customers.